Raludotatug is a humanized immunoglobulin G1-kappa (IgG1κ) monoclonal antibody that exhibits antineoplastic properties through its specific targeting of cadherin-6 (CDH6), and when conjugated to a cytotoxic payload to form the antibody-drug conjugate Raludotatug deruxtecan.Raludotatug has demonstrated promising research potential in heavily pretreated, platinum-sensitive ovarian cancer.